Key Highlights:
- Kenvue (KVUE, Financial) shares fell 6% after CEO's comments on seasonal product sales.
- Analysts' average one-year price target for Kenvue stands at $24.61.
- The company's stocks are currently rated as a "Hold" by brokerage firms.
In a surprising turn, Kenvue Inc. (KVUE) experienced a steep decline of 6% on Tuesday, its worst performance since its spin-off from Johnson & Johnson. This downturn was primarily triggered by CEO Thibaut Mongon's comments about challenges in selling seasonal products, such as allergy medications and sunscreen. The extended winter period has adversely affected the company's Q2 sales outlook.
Analyst Forecasts and Price Targets
Market analysts have provided a range of one-year price targets for Kenvue Inc. (KVUE, Financial), averaging out at $24.61. The projections span a high of $29.00 to a low of $22.00, suggesting an upside potential of 10.81% from the current trading price of $22.21. For a more comprehensive breakdown of these forecasts, refer to the Kenvue Inc (KVUE) Forecast page.
Brokerage Recommendations
According to the consensus of 18 brokerage firms, Kenvue Inc. is presently rated at an average brokerage recommendation of 2.7, which aligns with a "Hold" position. This rating system is scaled from 1 to 5, where 1 equates to a "Strong Buy" and 5 implies a "Sell".
Investors are closely monitoring how Kenvue will navigate through these recent challenges, looking for signs of stability and growth to determine if the current "Hold" recommendation will shift positively in the future.
